Trevi Therapeutics, Inc. · NASDAQ:TRVI
Heffernan Michael Thomas sold 39,373 Trevi Therapeutics, Inc. shares (Form 4)
Traded Sep 15, 2026 · Filed Sep 17, 2026
On Sep 15, 2026, Heffernan Michael Thomas (Director) sold 39,373 Trevi Therapeutics, Inc. shares at an average US$15.09 for US$594K under a trading plan, leaving 6,351 shares. Filed Sep 17, 2026 (Form 4).
- Sold
- 39,373 shares
- Price
- US$15.09 average (US$15.09 to US$15.88)
- Value
- US$594K
- Holding after
- 6,351 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Common Stock | Option exercise | 18,421 | US$3.04 | 24,772 | Direct |
| Sep 15, 2026 | Common Stock | Sale | 18,321 | US$15.09 | 6,451 | Direct |
| Sep 15, 2026 | Common Stock | Option exercise | 21,052 | US$3.33 | 27,403 | Direct |
| Sep 15, 2026 | Common Stock | Sale | 20,952 | US$15.09 | 6,451 | Direct |
| Sep 15, 2026 | Common Stock | Sale | 100 | US$15.88 | 6,351 | Direct |
Source
Related
- Trevi Therapeutics, Inc.
- Heffernan Michael Thomas
- Trevi Therapeutics, Inc. shareholders
- Schedule 13G/A · FMR LLC · Aug 6, 2026
- Schedule 13D/A · New Enterprise Associates 16, L.P. · May 7, 2026
- Schedule 13G/A · FMR LLC · May 6, 2026
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026
- Schedule 13D/A · New Enterprise Associates 16, L.P. · Feb 13, 2026